Astex drops amuvatinib for lung cancer after disappointing Phase II results
This article was originally published in Scrip
Dublin, California-based Astex Pharmaceuticals has ended the clinical development of amuvatinib (MP-470) after an evaluation of the first stage of a two-stage Phase II clinical trial with the multi-targeted tyrosine kinase inhibitor determined the response rate in platinum-refractory small cell lung cancer (SCLC) patients was 9.5%.
You may also be interested in...
Private Company Edition: Venture capital financings didn’t take a break during Thanksgiving week. In addition to the $800m Resilience raised to fund manufacturing services, SomaLogic closed a $121m series A round to fund its proteomic tools for drug discovery and diagnostics development.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.